VIDEO: Rate of uveitis recurrence reduced with Yutiq at 36 months
Click Here to Manage Email Alerts
In this Healio Video Perspective from the ASRS meeting, Ashkan M. Abbey, MD, of Texas Retina Associates discusses 36-month real-world data on the Yutiq implant for the treatment of chronic noninfectious uveitis.
The CALM registry phase 4 study collected data from 267 eyes that were implanted with Yutiq (0.18 mg fluocinolone acetonide intravitreal implant, Alimera Sciences). The most notable finding was the significant reduction of the rate of uveitis recurrence, according to Abbey.
“We can see from this real-world data using Yutiq that the Yutiq implant provides a long-term reduction in inflammatory flares and improvement in the OCT findings and also a stabilization of vision, with no new safety signals when it comes to its use,” he said.
Collapse
Abbey A. 36-month OCT outcomes from CALM: A registry evaluating treatment of chronic noninfectious uveitis with the 0.18 mg FAc intravitreal implant. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Read more about
Click Here to Manage Email Alerts